Capricor says Deramiocel BLA under active FDA review after AdCom vote
Capricor (CAPR) says Deramiocel’s BLA remains under active FDA review and it still sees a path to approval after a 3-9 AdCom vote, citing HOPE-3’s primary endpoint (p=0.029) and $~238M cash at Q2 end.